Try our beta test site
2112 studies found for:    "Acute myelocytic leukemia"
Show Display Options
Rank Status Study
21 Withdrawn ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)
Condition: Acute Myeloid Leukemia
Interventions: Drug: Vesanoid (ATRA);   Drug: AZACITIDINE (VIDAZA);   Drug: CYTARABINE
22 Completed A Randomized Study of Gemtuzumab Ozogamicin (GO) With Daunorubicine and Cytarabine in Untreated Acute Myeloid Leukemia (AML) Aged of 50-70 Years Old
Condition: Acute Myeloid Leukemia
Interventions: Drug: conventional chemotherapy (AraC + Daunorubicin),;   Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
23 Completed Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: Topotecan;   Drug: Fludarabine;   Drug: Cytarabine
24 Active, not recruiting Phase II Study of Bexarotene in Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Bexarotene
25 Recruiting HLA-mismatched Microtransplantation for High Risk Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: idarubicin;   Biological: microtransplantation
26 Completed
Has Results
Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients
Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152;   Drug: LDAC
27 Recruiting Protocol in Acute Myeloid Leukemia With FLT3-ITD
Condition: Acute Myeloid Leukemia
Interventions: Drug: Midostaurin;   Drug: Cytarabine;   Drug: Daunorubicin
28 Completed LAM07: Study to Analyze the Efficacy of a Risk Adapted Treatment Strategy, Including Gemtuzumab Ozogamicin (GO) During Consolidation, for Patients With Acute Myeloid Leukemia (AML)
Condition: Acute Myeloblastic Leukemia
Intervention: Drug: gemtuzumab
29 Completed Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML)
Condition: Acute Myeloblastic Leukaemia
Intervention: Drug: panobinostat
30 Completed
Has Results
Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)
Conditions: Acute Myeloid Leukemia (AML);   Adult Acute Myeloblastic Leukemia
Interventions: Drug: Lenalidomide;   Drug: Azacitidine
31 Completed Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Bortezomib
32 Terminated Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: AKN-028
33 Completed Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)
Condition: Acute Myeloid Leukaemia
Intervention: Drug: AZD1152
34 Completed Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Decitabine 15 mg/m2 i.v.
35 Terminated Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: Plerixafor granulocyte-colony stimulating factor
36 Terminated A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
Condition: Acute Myeloid Leukemia
Interventions: Procedure: Two post-remission strategies;   Drug: Idarubicin versus daunorubicin
37 Active, not recruiting A Phase 2 Trial to Evaluate the Efficacy and Safety of OCV-501 in Elderly Patients With Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Interventions: Drug: OCV-501;   Drug: Placebo
38 Completed Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and Older
Condition: Acute Myeloid Leukemia
Intervention: Drug: ZARNESTRA, tipifarnib, R115777
39 Recruiting MCLA-117 in Acute Myelogenous Leukemia
Conditions: Acute Myelogenous Leukemia;   Acute Myeloid Leukemia
Intervention: Drug: MCLA-117 bispecific antibody
40 Completed A Phase Ib, Open-label, Multi-center Dose-finding Study of Oral Panobinostat (LBH589) in Combination With Ara-C and Mitoxantrone as Salvage Therapy for Refractory or Relapsed Acute Myeloid Leukemia
Condition: Acute Myeloid Leukemia
Intervention: Drug: panobinostat/LBH589B

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.